Alzheimer's disease: Seeing the signs early
Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia. Data sour...
Gespeichert in:
Veröffentlicht in: | Journal of the American Academy of Nurse Practitioners 2009-11, Vol.21 (11), p.588-595 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 595 |
---|---|
container_issue | 11 |
container_start_page | 588 |
container_title | Journal of the American Academy of Nurse Practitioners |
container_volume | 21 |
creator | Leifer, Bennett P. |
description | Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia.
Data sources: Published literature on case detection, diagnosis, and treatment of AD.
Conclusions: There are a number of simple, accurate, and fast tools to facilitate case detection, including the Mini‐Mental State Examination. Once a diagnosis has been made, healthcare providers, patients, and caregivers can evaluate treatment options. Several medications are available for symptomatic treatment of AD, including the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and for later stage disease, the N‐methyl D‐aspartate (NMDA) receptor antagonist, memantine.
Implications for Practice: Early intervention is critical because a delay in treatment is associated with nonreversible symptom progression. Realistic treatment expectations include reduction in symptom severity and slowed decline in cognition, function, and behavior. Treatment may allow patients to retain independence longer and reduce the burden that advanced AD places on caregivers. |
doi_str_mv | 10.1111/j.1745-7599.2009.00436.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734132195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734132195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4066-6024ab7e4a523d75e02896fdb89eaaff38510f5fb53dc66b7a8b58f5bbbe19833</originalsourceid><addsrcrecordid>eNqNkE1PwkAQhjdGI4j-BdMbB9O6H91u18RDQxQlBI0f8bjZbadQbAG7EMFf79YSvTqXmWTfZyb7IOQRHBBXl_OAiJD7gksZUIxlgHHIomB7gLq_D4duxiHxqRS0g06snWNMOCXkGHWIlBhTirvoIim_ZlBUUPetlxUWtIUr7xmgWEy99Qw8W0wX1gNdl7tTdJTr0sLZvvfQ6-3Ny-DOHz8M7wfJ2E9DHEV-hGmojYBQc8oywQHTWEZ5ZmIJWuc5iznBOc8NZ1kaRUbo2PA458YYIDJmrIf67d5VvfzYgF2rqrAplKVewHJjlWAhYZRI7pJxm0zrpbU15GpVF5Wud4pg1ZhSc9UIUY0Q1ZhSP6bU1qHn-yMbU0H2B-7VuMB1G_gsStj9e7EaJcnETY73W76wa9j-8rp-V5Fggqu3yVA9yZH7MnlUhH0Ddi6EoQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734132195</pqid></control><display><type>article</type><title>Alzheimer's disease: Seeing the signs early</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Leifer, Bennett P.</creator><creatorcontrib>Leifer, Bennett P.</creatorcontrib><description>Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia.
Data sources: Published literature on case detection, diagnosis, and treatment of AD.
Conclusions: There are a number of simple, accurate, and fast tools to facilitate case detection, including the Mini‐Mental State Examination. Once a diagnosis has been made, healthcare providers, patients, and caregivers can evaluate treatment options. Several medications are available for symptomatic treatment of AD, including the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and for later stage disease, the N‐methyl D‐aspartate (NMDA) receptor antagonist, memantine.
Implications for Practice: Early intervention is critical because a delay in treatment is associated with nonreversible symptom progression. Realistic treatment expectations include reduction in symptom severity and slowed decline in cognition, function, and behavior. Treatment may allow patients to retain independence longer and reduce the burden that advanced AD places on caregivers.</description><identifier>ISSN: 1041-2972</identifier><identifier>EISSN: 1745-7599</identifier><identifier>DOI: 10.1111/j.1745-7599.2009.00436.x</identifier><identifier>PMID: 19900220</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Alzheimer Disease - diagnosis ; Alzheimer Disease - drug therapy ; Alzheimer's disease ; Cholinesterase Inhibitors - therapeutic use ; diagnosis ; Disease Progression ; Galantamine - therapeutic use ; Humans ; Memantine - therapeutic use ; Neuroprotective Agents - therapeutic use ; Nootropic Agents - therapeutic use ; Nursing ; Phenylcarbamates - therapeutic use ; primary care ; Primary Health Care ; Psychometrics ; Rivastigmine ; Time Factors ; treatment</subject><ispartof>Journal of the American Academy of Nurse Practitioners, 2009-11, Vol.21 (11), p.588-595</ispartof><rights>2009 The Author. Journal compilation © 2009 American Academy of Nurse Practitioners</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4066-6024ab7e4a523d75e02896fdb89eaaff38510f5fb53dc66b7a8b58f5bbbe19833</citedby><cites>FETCH-LOGICAL-c4066-6024ab7e4a523d75e02896fdb89eaaff38510f5fb53dc66b7a8b58f5bbbe19833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1745-7599.2009.00436.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1745-7599.2009.00436.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19900220$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leifer, Bennett P.</creatorcontrib><title>Alzheimer's disease: Seeing the signs early</title><title>Journal of the American Academy of Nurse Practitioners</title><addtitle>J Am Acad Nurse Pract</addtitle><description>Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia.
Data sources: Published literature on case detection, diagnosis, and treatment of AD.
Conclusions: There are a number of simple, accurate, and fast tools to facilitate case detection, including the Mini‐Mental State Examination. Once a diagnosis has been made, healthcare providers, patients, and caregivers can evaluate treatment options. Several medications are available for symptomatic treatment of AD, including the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and for later stage disease, the N‐methyl D‐aspartate (NMDA) receptor antagonist, memantine.
Implications for Practice: Early intervention is critical because a delay in treatment is associated with nonreversible symptom progression. Realistic treatment expectations include reduction in symptom severity and slowed decline in cognition, function, and behavior. Treatment may allow patients to retain independence longer and reduce the burden that advanced AD places on caregivers.</description><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>diagnosis</subject><subject>Disease Progression</subject><subject>Galantamine - therapeutic use</subject><subject>Humans</subject><subject>Memantine - therapeutic use</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Nootropic Agents - therapeutic use</subject><subject>Nursing</subject><subject>Phenylcarbamates - therapeutic use</subject><subject>primary care</subject><subject>Primary Health Care</subject><subject>Psychometrics</subject><subject>Rivastigmine</subject><subject>Time Factors</subject><subject>treatment</subject><issn>1041-2972</issn><issn>1745-7599</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1PwkAQhjdGI4j-BdMbB9O6H91u18RDQxQlBI0f8bjZbadQbAG7EMFf79YSvTqXmWTfZyb7IOQRHBBXl_OAiJD7gksZUIxlgHHIomB7gLq_D4duxiHxqRS0g06snWNMOCXkGHWIlBhTirvoIim_ZlBUUPetlxUWtIUr7xmgWEy99Qw8W0wX1gNdl7tTdJTr0sLZvvfQ6-3Ny-DOHz8M7wfJ2E9DHEV-hGmojYBQc8oywQHTWEZ5ZmIJWuc5iznBOc8NZ1kaRUbo2PA458YYIDJmrIf67d5VvfzYgF2rqrAplKVewHJjlWAhYZRI7pJxm0zrpbU15GpVF5Wud4pg1ZhSc9UIUY0Q1ZhSP6bU1qHn-yMbU0H2B-7VuMB1G_gsStj9e7EaJcnETY73W76wa9j-8rp-V5Fggqu3yVA9yZH7MnlUhH0Ddi6EoQ</recordid><startdate>200911</startdate><enddate>200911</enddate><creator>Leifer, Bennett P.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200911</creationdate><title>Alzheimer's disease: Seeing the signs early</title><author>Leifer, Bennett P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4066-6024ab7e4a523d75e02896fdb89eaaff38510f5fb53dc66b7a8b58f5bbbe19833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>diagnosis</topic><topic>Disease Progression</topic><topic>Galantamine - therapeutic use</topic><topic>Humans</topic><topic>Memantine - therapeutic use</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Nootropic Agents - therapeutic use</topic><topic>Nursing</topic><topic>Phenylcarbamates - therapeutic use</topic><topic>primary care</topic><topic>Primary Health Care</topic><topic>Psychometrics</topic><topic>Rivastigmine</topic><topic>Time Factors</topic><topic>treatment</topic><toplevel>online_resources</toplevel><creatorcontrib>Leifer, Bennett P.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Nurse Practitioners</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leifer, Bennett P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alzheimer's disease: Seeing the signs early</atitle><jtitle>Journal of the American Academy of Nurse Practitioners</jtitle><addtitle>J Am Acad Nurse Pract</addtitle><date>2009-11</date><risdate>2009</risdate><volume>21</volume><issue>11</issue><spage>588</spage><epage>595</epage><pages>588-595</pages><issn>1041-2972</issn><eissn>1745-7599</eissn><abstract>Purpose: Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs). PCPs must therefore be watchful for signs and symptoms of AD, and should screen elderly patients who complain of memory and cognitive problems for dementia.
Data sources: Published literature on case detection, diagnosis, and treatment of AD.
Conclusions: There are a number of simple, accurate, and fast tools to facilitate case detection, including the Mini‐Mental State Examination. Once a diagnosis has been made, healthcare providers, patients, and caregivers can evaluate treatment options. Several medications are available for symptomatic treatment of AD, including the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, and for later stage disease, the N‐methyl D‐aspartate (NMDA) receptor antagonist, memantine.
Implications for Practice: Early intervention is critical because a delay in treatment is associated with nonreversible symptom progression. Realistic treatment expectations include reduction in symptom severity and slowed decline in cognition, function, and behavior. Treatment may allow patients to retain independence longer and reduce the burden that advanced AD places on caregivers.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19900220</pmid><doi>10.1111/j.1745-7599.2009.00436.x</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1041-2972 |
ispartof | Journal of the American Academy of Nurse Practitioners, 2009-11, Vol.21 (11), p.588-595 |
issn | 1041-2972 1745-7599 |
language | eng |
recordid | cdi_proquest_miscellaneous_734132195 |
source | Wiley-Blackwell Journals; MEDLINE |
subjects | Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Alzheimer's disease Cholinesterase Inhibitors - therapeutic use diagnosis Disease Progression Galantamine - therapeutic use Humans Memantine - therapeutic use Neuroprotective Agents - therapeutic use Nootropic Agents - therapeutic use Nursing Phenylcarbamates - therapeutic use primary care Primary Health Care Psychometrics Rivastigmine Time Factors treatment |
title | Alzheimer's disease: Seeing the signs early |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T19%3A04%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alzheimer's%20disease:%20Seeing%20the%20signs%20early&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Nurse%20Practitioners&rft.au=Leifer,%20Bennett%20P.&rft.date=2009-11&rft.volume=21&rft.issue=11&rft.spage=588&rft.epage=595&rft.pages=588-595&rft.issn=1041-2972&rft.eissn=1745-7599&rft_id=info:doi/10.1111/j.1745-7599.2009.00436.x&rft_dat=%3Cproquest_cross%3E734132195%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734132195&rft_id=info:pmid/19900220&rfr_iscdi=true |